Pelthos Therapeutics Inc. Stock Price

Catalysts About Pelthos Therapeutics Pelthos Therapeutics focuses on topical prescription treatments for pediatric and dermatologic infections, led by ZELSUVMI for molluscum contagiosum and XEPI for impetigo in the U.S. What are the underlying business or industry changes driving this perspective? First and only FDA approved at home prescription therapy for molluscum contagiosum, with 17 million people affected in the U.S. and about 6 million new cases a year, positions ZELSUVMI to address a large treated and previously under treated pool of patients, which is most relevant for long term revenue potential.Read more

Catalysts About Pelthos Therapeutics Pelthos Therapeutics focuses on prescription topical therapies for pediatric and dermatologic infections, centered today on ZELSUVMI for molluscum contagiosum and the recently acquired XEPI for impetigo in the U.S. What are the underlying business or industry changes driving this perspective? Although ZELSUVMI is the first and only FDA approved at home therapy for molluscum contagiosum in a U.S. population with an estimated 6,000,000 new cases each year, the company still needs to convert broad disease prevalence into sustained prescription volumes across its roughly 10,000 target accounts.Read more

Catalysts About Pelthos Therapeutics Pelthos Therapeutics develops and commercializes innovative topical treatments for pediatric and dermatologic infections, anchored by its first in class at home therapy ZELSUVMI and the recently acquired XEPI. What are the underlying business or industry changes driving this perspective?Read more